New Hampshire's decision to end Medicaid coverage for GLP-1 medications used to treat obesity has sparked concerns about access and stigma surrounding the disease.

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

GSK plc’s GSK Specialty Medicines business has become the company's primary growth engine, accounting for more than 40% of ...

Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth in the ...

Health insurance is one of those topics many people know they need but rarely feel excited to explore. It can seem crowded with unfamiliar terms, fine print, and numbers that are not always easy to ...

Low-dose ICS remain essential for every asthma patient, and GINA/CFA guidance favors phenotype-tailored step-up strategies ...

New results from the Phase 3 SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral ...

On May 5, 2025, the Global Initiative For Asthma (GINA) published the 2026 update to their Global Strategy for Asthma ...

The Global Hypertension Report by the World Health Organization (WHO) revealed that 1.4 billion people were living with ...

Kennedy has responded to outbreaks of measles and whooping cough in the US by pushing disinformation about vaccines.

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...

Zoci Intracranial ORR -- Achieved a 62.5% confirmed intracranial overall response rate and nearly 69% best overall ...